Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus QBREXZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus QBREXZA.
CANTIL vs QBREXZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Selective D1 and D5 dopamine receptor antagonist; reduces dopamine-mediated vasodilation in choroidal blood vessels, decreasing choroidal thickness and neovascularization.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
1 capsule (40 mg) orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is approximately 150 hours (range 120-200 hours), supporting once-daily dosing without significant accumulation.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal: approximately 30% as unchanged drug; fecal: approximately 60% as metabolites and parent compound; biliary excretion contributes to fecal elimination.
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic